Alliance of Digistain & CORE Diagnostics aims to redefine Breast Cancer care with AI
A clinical laboratory focused on next-generation diagnostics for disease stratification and therapy selection CORE Diagnostics, has joined hands with Digistain. According to the company, this partnership will enable them to bring UK's first Breast Cancer Risk Profiling Technology, Digistain, to India, Nepal, Bhutan and Bangladesh.
Digistain is a remarkable digital solution for cancer grading and prognosis, approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA). The company offers a rapid, affordable, and AI-enabled solution to predict the symptoms of post-surgery breast cancer recurrence. The high-end technology is crafted specifically to enable the cancer patients to avoid undergoing unnecessary chemotherapy.
The healthtech startup Digistain was created with the necessary inputs from over 1,500 oncologists and has been successfully trialed at prominent cancer centers, such as Nottingham University NHS Trust, the National Institute of Healthcare Research (NIHR), and Cancer Research UK.
The company said in a press release, the introduction of Digistain in India and its vicinity through this partnership is expected to revolutionize the healthcare industry’s approach to breast cancer treatment.
Through the AI based technology, Digistain developed the potential to enhance diagnostic accuracy, reduce treatment costs, and ultimately save lives. This revolutionary collaboration with India’s broader healthcare objectives aims to utilize the power of innovative solutions to address pressing healthcare challenges and improve patient care nationwide.
The Chief Executive Officer of Digistain, Dr. Hemmel Amrania, PhD, will be actively participating and contributing towards developing this technology.
The CEO of CORE Diagnostics, Dinesh Chauhan has 25 years of rich experience in various verticals across the Diagnostics Industry and has witnessed the industry's transition. Previously, he has introduced numerous innovative diagnostic tests to India and was contributed towards creating a market for the new tests.
About this new venture, Chauhan said, “This partnership represents a significant step forward in the fight against breast cancer by providing a faster, more accurate, and cost-effective approach to cancer prognosis and treatment. CORE Diagnostics and Digistain® are committed to improving patient outcomes and transforming the landscape of healthcare.”
.jpg "Karya Kalpa : Creating Spaces that Tell Unique Stories, Inspiring Comfort with Ecofriendly, User-friendly, & Budget-friendly Solutions")
.jpg "Kasaza Art & Design: Redefining Creative Ex-pression & Crafting Digital Artistry")